However, several dose-dependent side effects such as pruritus, increased cholesterol and LDL along with lower HDL in plasma were observed in NASH patients treated with an FXR agonist (Fiorucci et al., 2020). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.